Details Behind Johnson & Johnson’s $5.5 Billion Talcum Powder Settlement

In the latest update on the ongoing talcum powder cancer litigation, Johnson & Johnson (J&J) has proposed a $5.5 billion settlement to resolve nearly 80,000 lawsuits alleging that its talcum powder products, including baby powder, caused the disease. This settlement, announced on July 27, 2026, marks a potential conclusion to over a decade of litigation surrounding the safety of talc-based products.

Overview of the Talcum Powder Settlement

The proposed talcum powder settlement aims to address claims from approximately 76,000 plaintiffs involved in federal multidistrict litigation in New Jersey and related state court proceedings. The agreement is contingent upon the acceptance of at least 95% of the remaining claimants, a threshold that must be met for the settlement to become final.

Key Details of the Settlement

• Total Amount: $5.5 billion
• Number of Claims: Approximately 76,000
• Jurisdiction: Federal multidistrict litigation in New Jersey and related state courts
• Acceptance Requirement: 95% of claimants must agree to the settlement

This settlement is particularly noteworthy as it represents one of the largest resolutions in the history of the talcum powder litigation, which has seen numerous trials, mixed verdicts, and failed bankruptcy attempts by J&J to manage its liabilities.

Background of the Talcum Powder Cancer Litigation

The legal battles surrounding Johnson & Johnson’s widely used talcum powder products date back more than a decade, with plaintiffs alleging that the talc used in some products was contaminated with asbestos, a known carcinogen. Thousands of lawsuits have also alleged that long-term use of talc-based products in the genital area contributed to the development of ovarian cancer.

Over the years, juries have returned several significant verdicts against Johnson & Johnson. In 2016, a St. Louis jury awarded $55 million to a South Dakota woman who claimed her ovarian cancer was caused by J&J’s talc products. In 2018, another St. Louis jury awarded $4.69 billion to 22 women and their families in one of the largest verdicts in the talcum powder litigation. That award was later reduced on appeal to approximately $2.12 billion, and despite further efforts by J&J to overturn the judgment, the U.S. Supreme Court ultimately declined to review the claim.

Finally, in 2020, amid mounting product liability lawsuits and declining demand, J&J ceased sales of talc-based baby powder in the U.S. and Canada. The company later discontinued its talc-based baby powder globally.

J&J’s Failed Bankruptcy Attempts

Johnson & Johnson has also made several attempts to resolve the widespread talc litigation outside of individual trials. Beginning in 2021, the company pursued a series of Chapter 11 bankruptcy proceedings involving subsidiaries that had been assigned its talc-related liabilities.

Its first two bankruptcy filings were dismissed. As part of its second bankruptcy filing in 2023, J&J proposed an approximately $8.9 billion settlement to resolve current and future talc claims. A third bankruptcy proceeding, filed in 2024 as part of another effort to resolve ovarian and other gynecological cancer claims, was dismissed by a federal bankruptcy judge in March 2025 after the court declined to confirm the proposed settlement plan.

Following the third bankruptcy dismissal, J&J returned to defending talc claims in civil courts. In December 2025, a California jury awarded $40 million to two women who alleged that decades of using J&J’s talc-based products caused their ovarian cancer.

Details of the Latest Talcum Powder Settlement Agreement

In July 2026, Johnson & Johnson announced this new $5.5 billion agreement aimed at resolving approximately 76,000 remaining ovarian cancer claims. Unlike the company’s previous bankruptcy proposals, the latest agreement is being pursued outside of bankruptcy and is conditioned on participation by at least 95% of the remaining claims.

Despite the proposed settlement, J&J continues to maintain that its talc products are safe and do not cause cancer, a position the company has consistently maintained throughout the litigation.

What the $5.5 Billion Talcum Powder Settlement Means for Claimants

The proposed $5.5 billion agreement could resolve approximately 76,000 remaining talcum powder cancer claims against Johnson & Johnson. The agreement, however, is not yet final. The proposed agreement also does not encompass every type of talc-related lawsuit that has been brought against Johnson & Johnson. The latest settlement focuses on ovarian cancer claims. J&J says it has separately resolved approximately 95% of filed talcum powder mesothelioma lawsuits, all state consumer protection claims, and its disputes with talc suppliers.

What Happens Next in the J&J Talcum Powder Litigation?

The announcement of the $5.5 billion agreement does not immediately end the talcum powder ovarian cancer litigation. The proposed resolution must first satisfy its participation requirement, which calls for the express participation of at least 95% of the remaining claims.

If the necessary participation and other settlement conditions are met, the agreement could resolve nearly all of the remaining ovarian cancer claims pending against J&J in federal and state courts.

The talcum powder litigation has produced substantial verdicts for some plaintiffs, defense verdicts for J&J, appellate reversals, multiple bankruptcy proceedings, and several settlement efforts over more than a decade. Whether the latest agreement brings the ovarian cancer litigation substantially to an end will depend on whether the settlement’s participation and other requirements are ultimately satisfied.